Photo

Photo detail

Graphic Courtesy of Avidity Biosciences
Avidity Biosciences develops RNA therapies and drugs to treat muscular disorders and other rare diseases.

Stories this photo appears in:

Avidity Biosciences CEO Reflects on Going Public in 2020

BIOTECH: Sarah Boyce Speaks About Completely Virtual IPO Process

The past year has changed everything about what it means for a biotech company to go public, according to Avidity Biosciences President and CEO Sarah Boyce.

Tease photo